Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma - Full Text View

Sponsor:	Sepracor, Inc.
Information provided by:	Sepracor, Inc.
ClinicalTrials.gov Identifier:	NCT00073827

Purpose

The primary purpose of this study was to investigate the efficacy of levalbuterol compared to a placebo and compared to albuterol in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).

Condition	Intervention	Phase
Asthma	Drug: levalbuterol tartrate MDI Drug: racemic albuterol MDI Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study
Official Title:	An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

Resource links provided by NLM:

MedlinePlus related topics: Asthma

Drug Information available for: Albuterol Levalbuterol hydrochloride Albuterol sulfate Levalbuterol tartrate

U.S. FDA Resources

Further study details as provided by Sepracor, Inc.:

Primary Outcome Measures:

percent change in FEV1 from visit predose averaged over the 8-week double-blind period [ Time Frame: Weeks 0, 4, 8 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

area under the FEV1 percent change curve from visit pre-dose and from study baseline curves averaged over the double-blind period [ Time Frame: Weeks 0, 4, 8 ] [ Designated as safety issue: No ]
peak percent change in FEV1 from study baseline [ Time Frame: Weeks 0, 4, 8 ] [ Designated as safety issue: No ]
peak change in FEV1 from visit predose [ Time Frame: Weeks 0, 4, 8 ] [ Designated as safety issue: No ]
peak percent of predicted FEV1 [ Time Frame: Weeks 0, 4, 8 ] [ Designated as safety issue: No ]
area under the FEV1 curve (AUC) [ Time Frame: Weeks 0, 4, 8 ] [ Designated as safety issue: No ]
peak change and peak percent change in FEF25-75% from visit predose [ Time Frame: Weeks 0, 4, 8 ] [ Designated as safety issue: No ]
peak change and peak percent change in FVC from visit predose [ Time Frame: Weeks 0, 4, 8 ] [ Designated as safety issue: No ]

Enrollment:	445
Study Start Date:	May 2002
Study Completion Date:	January 2003
Primary Completion Date:	January 2003 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental levalbuterol MDI 90 mcg QID	Drug: levalbuterol tartrate MDI levalbuterol 90 mcg QID
2: Active Comparator racemic albuterol MDI 180 mcg QID	Drug: racemic albuterol MDI racemic albuterol 180 mcg QID
3: Placebo Comparator Placebo MDI QID	Drug: Placebo Placebo MDI QID

Detailed Description:

This was a Phase III, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group study of up to 9 weeks in duration. Seven days of QID single-blind placebo administration (via MDI) was followed by 56 days of QID double-blind active treatment. Following the run-in period, each subject was randomized to one of the following three treatments: levalbuterol HFA MDI 90 mcg (2 actuations of 45 mcg), racemic albuterol HFA MDI 180 mcg (2 actuations of 90 mcg), or placebo (2 actuations). Subjects were randomized in a 2:1:1 ratio of levalbuterol to racemic albuterol to placebo. In order to maintain blinding of the device, a placebo dose was administered with each treatment.

Eligibility

Ages Eligible for Study:	12 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Willing and able to comply with the study procedures and visit schedules
Male or female, at least 12 years of age
Female subjects 12-60 years of age must have a negative serum pregnancy test at study start.
Women of child bearing potential must be using an acceptable method of birth control
Have a documented diagnosis of asthma for a minimum of 6 months prior to study start
Must have stable baseline asthma and have been using a B-adrenergic agonist, and/or anti-asthma anti-inflammatory medication, and/or OTC asthma medication for at least 6 months prior to study start
Must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function
Must have a chest X-ray that is not diagnostic of pneumonia, atelectasis, pulmonary fibrotic disease, pneumothorax, chronic obstructive pulmonary disease, etc.
Must be able to complete the diary cards and medical event calendars reliably on a daily basis, understand dosing instructions, and demonstrate how to use the MiniWright PEF meter.

Exclusion Criteria

Female subject who is pregnant or lactating
Have participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another clinical trial
Subject whose schedule prevents him or her from taking the first daily dose of study medication and/or starting study visits before 9 AM
Subject who has travel commitments during the study that would interfere with trial measurements or compliance
Have a history of hospitalization for asthma within 45 days prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery
Have a known sensitivity to levalbuterol or racemic albuterol, or any excipients in any of these formulations
Subject using any prescription drug with which albuterol sulfate administration is contraindicated
Subject with currently diagnosed life-threatening asthma
History of cancer (exception: basal cell carcinoma in remission).
Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication
History of substance abuse or drug abuse within 12 months preceding study start
Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start
Documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis
Have suffered from a clinically significant upper or lower respiratory tract infection in the 2 weeks prior to study start
Subject who is a staff member or relative of a staff member

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00073827

Hide Study Locations

Locations

United States, Alabama
Alabama Asthma and Allergy Center
Homewood, Alabama, United States, 35209
MDC Research
Mobile, Alabama, United States, 36607
United States, California
Bensch Research Associates
Stockton, California, United States, 95207
Allergy & Asthma Prevention & Treatment Center
San Diego, California, United States, 92131
Allergy Research Foundation, Inc.
Los Angeles, California, United States, 90025
Clinical Trials of Orange County
Orange, California, United States, 92868
Allergy & Asthma Assoc. of Santa Clara Valley Research Center
San Jose, California, United States, 95117
Allergy & Asthma Specialists Medical Group
Huntington Beach, California, United States, 92647
Allergy & Asthma Medical Group & Research Center
San Diego, California, United States, 92123
Integrated Research Group
Corona, California, United States, 92879
Radiant Research, Inc.
Encinitas, California, United States, 92024
Allergy Associates Medical Group
San Diego, California, United States, 92120
Allergy & Asthma Medical Group of Diablo Valley, Inc.
Danville, California, United States, 94526
Southern California Research Center
Viejo, California, United States, 92691
Allergy, Asthma & Respiratory Care Center
Long Beach, California, United States, 90806
United States, Colorado
Clinical Research Centers of Colorado PC
Englewood, Colorado, United States, 80112
National Jewish Medical & Research Center
Denver, Colorado, United States, 80206
Asthma & Allergy Associates, PC
Pueblo, Colorado, United States, 81001
United States, Florida
Office of Ronald Saff
Tallahassee, Florida, United States, 32308
United States, Georgia
Aeroallergy Research Laboratories of Savannah, Inc.
Savannah, Georgia, United States, 31406
United States, Hawaii
Radiant Research Honolulu
Honolulu, Hawaii, United States, 96814
United States, Indiana
Clinical Research Center of Indiana
Indianapolis, Indiana, United States, 46208
United States, Louisiana
Northshore Medical Research
Slidell, Louisiana, United States, 70458
Allergy & Asthma Care Specialists
Metairie, Louisiana, United States, 70006
United States, Maryland
University of Maryland School of Medicine
Baltimore, Maryland, United States
United States, Massachusetts
Northeast Medical Research Associates, Inc.
N. Dartmouth, Massachusetts, United States, 02747
PCHI
Needham, Massachusetts, United States, 02494
Center for Clinical Research
Taunton, Massachusetts, United States, 02780
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
United States, Minnesota
Clinical Research Institute
Minneapolis, Minnesota, United States, 55402
United States, Mississippi
Mississippi Asthma & Allergy Clinic
Jackson, Mississippi, United States
United States, Missouri
Office of Clinical Research, University of Missouri-Columbia
Columbia, Missouri, United States, 65212
Division of Allergy & Immunology, Washington Univ School of Med
St. Louis, Missouri, United States, 63110
The Clinical Research Center, LLC
St. Louis, Missouri, United States, 63141
St. Louis University
St. Louis, Missouri, United States, 63110
The Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
United States, New Jersey
Pulmonary and Allergy Associates
Springfield, New Jersey, United States, 07081
Princeton Center for Clinical Research
Princeton, New Jersey, United States, 08540
United States, New York
AAIR Research Center
Rochester, New York, United States, 14618
PCCS
Albany, New York, United States, 12205
United States, North Carolina
Raleigh Pediatric Associates
Raleigh, North Carolina, United States, 27609
Regional Allergy & Asthma Consultants
Asheville, North Carolina, United States, 28801
Cornerstone Research Care
High Point, North Carolina, United States, 27262
United States, Ohio
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States, 45231
United States, Oregon
Allergy & Asthma Research
Eugene, Oregon, United States, 97401
Allergy Associates Research Center, LLC
Portland, Oregon, United States, 97213
United States, Pennsylvania
University of Pittsburgh Division of Pulmonary
Pittsburgh, Pennsylvania, United States, 15213
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140
Asthma & Allergy Research Associates
Chester, Pennsylvania, United States, 19013
Children's Hospital of Pittsburgh Division of Allergy, Immunology & Infectious Diseases
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
Allergy & Asthma Consultants, LLP
Mt. Pleasant, South Carolina, United States, 29464
Radiant Research
Charleston, South Carolina, United States, 29407
Office of Neil Kao
Greenville, South Carolina, United States, 29607
United States, Texas
Breath of Life Research Institute
Houston, Texas, United States, 77054
Allergy & Asthma Center
Waco, Texas, United States
Lung Diagnostics
San Antonio, Texas, United States
North Texas Institute for Clinical Trials
Fort Worth, Texas, United States, 76132
Allergy & Asthma Research Associates
Dallas, Texas, United States, 75231
Office of Constantine Saadeh
Amarillo, Texas, United States, 79106
United States, Virginia
Children's Hospital of the Kings Daughters
Norfolk, Virginia, United States, 23507
Pulmonary Associates of Richmond, Inc.
Richmond, Virginia, United States, 23225
United States, Washington
ASTHMA, Inc.
Seattle, Washington, United States, 98105
United States, Wisconsin
Allergic Diseases, SC
West Allis, Wisconsin, United States, 53227

Sponsors and Collaborators

Sepracor, Inc.

More Information

No publications provided

Responsible Party:	Sepracor Inc ( Xopenex Medical Director )
Study ID Numbers:	051-353
Study First Received:	December 9, 2003
Last Updated:	June 6, 2008
ClinicalTrials.gov Identifier:	NCT00073827 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Sepracor, Inc.:

adolescent
adult
asthma
levalbuterol
bronchoconstriction

Additional relevant MeSH terms:

Respiratory System Agents
Neurotransmitter Agents
Bronchial Diseases
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Albuterol
Physiological Effects of Drugs
Reproductive Control Agents
Adrenergic Agonists
Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Tocolytic Agents

Therapeutic Uses
Immune System Diseases
Adrenergic beta-Agonists
Asthma
Anti-Asthmatic Agents
Pharmacologic Actions
Autonomic Agents
Lung Diseases
Hypersensitivity, Immediate
Peripheral Nervous System Agents
Bronchodilator Agents
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on November 25, 2009